Prakt. lékáren. 2007; 3(5): 206-209

Farmakologická a nefarmakologická léčba arytmií

MUDr. Miroslav Novák CSc1, MUDr. Zuzana Nováková Ph.D2
1 I. interní kardioangiologická klinika FN u sv. Anny v Brně
2 Fyziologický ústav LF Masarykovy univerzity, Brno

Léčba arytmií doznává v posledních letech na základě pochopení mechanizmů jejich vzniku významný posun – většinu zejména symptomatických arytmií je možno vyléčit katétrovou ablací. Pro akutní situace, ale i pro běžnou praxi, je však nutno nadále znát indikace, účinky a dávky jednotlivých antiarytmik. Stručně jsou zmíněny i indikace k implantaci kardiostimulátorů a implantabilních kardioverterů-defibrilátorů.

Keywords: nefarmakologická a farmakologická léčba arytmií, antiarytmika, katétrová ablace, trvalá kardiostimulace, implantabilní kardiovertery-defibrilátory

Published: December 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novák M, Nováková Z. Farmakologická a nefarmakologická léčba arytmií. Praktické lékárenství. 2007;3(5):206-209.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aschermann M. Kardiologie. Praha: Galén, 2004. 1481 s.
    2. Baker BM, Lindsay BD, Bromberg BI et al. Catheter ablation of clinical intraatrial reentrant tachycardias resulting from previous atrial surgery: Localizing and transsecting the critical isthmus. J Am Coll Cardiol 1996; 28: 411-417. Go to original source... Go to PubMed...
    3. Bytešník J. Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2005, 47(9), Suppl.: 41-57.
    4. Clague JR, Dagres N, Kottkapm H et al. Targeting the slow pathway for atrioventricular nodal re-entrant tachycardia: initial results and long-term follow-up in 379 consecutive patients. Eur Heart J. 2001; 22: 82-88. Go to original source... Go to PubMed...
    5. Čihák R, Heinc P. Doporučení pro léčbu pacientů s fibrilací síní. Cor Vasa 2004; 46(3): K35-K44.
    6. Doni F, Manfredi M, Piemonti C, et al. New onset atrial flutter termination by overdrive transesophageal pacing: effects of different protocols of stimulation. Europace. 2000; 2: 292-296. Go to original source... Go to PubMed...
    7. Fiala M. Doporučené postupy pro diagnostiku a léčbu supraventrikulárních tachyarytmií. Česká kardiologická společnost, Cor Vasa 2005; 47(9), Suppl: 18-39.
    8. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666. Go to original source... Go to PubMed...
    9. Hoffmann E, Rithmann C, Nimmermann P et al. Clinical experience with electroanatomic mapping of ectopic atrial tachycardia. PACE 2002; 25: 49-56. Go to original source... Go to PubMed...
    10. Kautzner J, Čihák R, Peichl P et al. Catheter ablation of ventricular tachycardia following myocardial infarction using three-dimensional electroanatomical mapping. PACE 2003; 26, p. II: 342-347. Go to original source... Go to PubMed...
    11. Lee RJ, Kalman JM, Fitzpatrick AP et al. Radiofrequency catheter modification of the sinus node for "inappropriate sinus tachycardia. Circulation.1995; 92: 2919-2928. Go to original source... Go to PubMed...
    12. Lip GY, Kamath S. Thromboprophylaxis for atrial flutter. Eur Heart J. 2001; 22: 984-987. Go to original source... Go to PubMed...
    13. López-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on ß-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004: 25: 1341-1362. Go to original source... Go to PubMed...
    14. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-2628. Go to original source... Go to PubMed...
    15. Stambler BS, Wood MA, Ellenbogen KA, et al. for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996; 94: 1613-1621. Go to original source... Go to PubMed...
    16. Sweeney MO. Cardioversion and defibrillation. In: Intensive Care Medicine. Irwin RS, Rippe JM. Philadelphia: Lippincott Williams and Wilkins, 2003, 73-80.
    17. Táborský M. Zásady pro implantace kardiostimulátorů a implantabilních kardioverterů-defibrilátorů. Cor Vasa 2005; 47(9), Suppl.: 59-68.
    18. Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amidarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol. 1999; 10: 1180-1187. Go to original source... Go to PubMed...
    19. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 1995; 92: 2550-2557.
    20. Zipes D, Jalife J: Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: W.B. Saunders Company, 2000: 1111.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.